Dr. Reddy's Laboratories Q2 FY26 Earnings Call Transcript

Dr. Reddy's Laboratories reported its Q2 FY26 earnings, highlighting a steady performance with near double-digit growth despite lower Lenalidomide sales. The company achieved consolidated revenues of ₹8,805 crores ($992 million), a 9.8% year-over-year growth. EBITDA margin stood at 26.7%. Key highlights include the integration of the consumer healthcare business, progress in biosimilars like Abatacept and Semaglutide, and regulatory advancements. The company also discussed its focus on cost efficiencies, strategic partnerships, and future growth drivers, including the potential launch of Semaglutide in multiple markets. The management remains confident in achieving sustainable growth and maintaining margins in the coming years.